...a managing partner at Merriman Partners; and F. Richard Nichol, retired chairman and CEO of CoCensys...

...Diego, Calif. Business: Autoimmune/Inflammation, Pulmonary Appointed: F. Richard Nichol, retired president, CEO and chairman of CoCensys Inc....

...Medinor $7.3 Procept Pacific Pharma $6.4 Avecia Boston Biosystems $6.0 Parexel CEMAF $6.0 Purdue Pharma CoCensys...

...all outstanding shares of COCN for $1.16 per share in cash (see BioCentury, Aug. 9). CoCensys Inc....

...of regulatory affairs and quality assurance, formerly EVP of product development and regulatory affairs at CoCensys Inc. WIR...

...up $0.625 on the week, while CYP finished at $2, down $0.125 (see Noteworthy, A4). CoCensys...

...assumption of debt and purchase of preferred stock outstanding, is expected to be $9.5 million. CoCensys Inc....

...Cytovia, which develops apoptosis inhibitors and screening cell technology, to Domain (see BioCentury, May 17). CoCensys Inc....

...of its Cytovia shares. After the repurchase, $1.9 million in preferred stock will remain outstanding. CoCensys Inc....

...of $805,000 in the first quarter, and had $9 million in cash at March 31. CoCensys Inc....